Vanguard Group’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $15.9M | Buy |
582,263
+15,522
| +3% | +$272K | ﹤0.01% | 2730 |
|
|
2025
Q3 | $8.5M | Buy |
566,741
+79,822
| +16% | +$919K | ﹤0.01% | 3054 |
|
|
2025
Q2 | $6.3M | Buy |
486,919
+397,968
| +447% | +$3.43M | ﹤0.01% | 3128 |
|
|
2025
Q1 | $690K | Buy |
88,951
+62,557
| +237% | +$738K | ﹤0.01% | 3811 |
|
|
2024
Q4 | $599K | Hold |
26,394
| – | – | ﹤0.01% | 3892 |
|
|
2024
Q3 | $148K | Sell |
26,394
-215
| -0.8% | -$2.21K | ﹤0.01% | 4168 |
|
|
2024
Q2 | $357K | Hold |
26,609
| – | – | ﹤0.01% | 4075 |
|
|
2024
Q1 | $463K | Hold |
26,609
| – | – | ﹤0.01% | 4033 |
|
|
2023
Q4 | $547K | Buy |
26,609
+16
| +0.1% | +$224 | ﹤0.01% | 4001 |
|
|
2023
Q3 | $440K | Hold |
26,593
| – | – | ﹤0.01% | 4094 |
|
|
2023
Q2 | $691K | Buy |
26,593
+691
| +3% | +$17.9K | ﹤0.01% | 4017 |
|
|
2023
Q1 | $654K | Hold |
25,902
| – | – | ﹤0.01% | 4040 |
|
|
2022
Q4 | $648K | Buy |
25,902
+10
| +0% | +$256 | ﹤0.01% | 4034 |
|
|
2022
Q3 | $692K | Buy |
25,892
+7,447
| +40% | +$237K | ﹤0.01% | 4114 |
|
|
2022
Q2 | $599K | Buy |
18,445
+9,682
| +110% | +$308K | ﹤0.01% | 4240 |
|
|
2022
Q1 | $320K | Sell |
8,763
-12,122
| -58% | -$459K | ﹤0.01% | 4463 |
|
|
2021
Q4 | $1.12M | Sell |
20,885
-1,468
| -7% | -$98.7K | ﹤0.01% | 4240 |
|
|
2021
Q3 | $1.65M | Buy |
22,353
+1,292
| +6% | +$716K | ﹤0.01% | 4115 |
|
|
2021
Q2 | $17.7M | Buy |
21,061
+3,089
| +17% | +$2.78M | ﹤0.01% | 2913 |
|
|
2021
Q1 | $15.4M | Buy |
17,972
+218
| +1% | +$179K | ﹤0.01% | 2929 |
|
|
2020
Q4 | $16.2M | Buy |
17,754
+11,151
| +169% | +$10.5M | ﹤0.01% | 2742 |
|
|
2020
Q3 | $8.01M | Buy |
6,603
+4,173
| +172% | +$2.77M | ﹤0.01% | 2895 |
|
|
2020
Q2 | $886K | Sell |
2,430
-212
| -8% | -$94.7K | ﹤0.01% | 3639 |
|
|
2020
Q1 | $1.21M | Sell |
2,642
-7
| -0.3% | -$2.73K | ﹤0.01% | 3442 |
|
|
2019
Q4 | $530K | Sell |
2,649
-29
| -1% | -$6.57K | ﹤0.01% | 3784 |
|
|
2019
Q3 | $665K | Sell |
2,678
-170
| -6% | -$258K | ﹤0.01% | 3755 |
|
|
2019
Q2 | $7.13M | Buy |
2,848
+16
| +0.6% | +$47.4K | ﹤0.01% | 3042 |
|
|
2019
Q1 | $11.5M | Buy |
2,832
+380
| +15% | +$1.47M | ﹤0.01% | 2752 |
|
|
2018
Q4 | $7.55M | Buy |
2,452
+352
| +17% | +$1.52M | ﹤0.01% | 2906 |
|
|
2018
Q3 | $12.3M | Buy |
2,100
+272
| +15% | +$1.04M | ﹤0.01% | 2815 |
|
|
2018
Q2 | $6.41M | Buy |
1,828
+38
| +2% | +$139K | ﹤0.01% | 3118 |
|
|
2018
Q1 | $7.96M | Buy |
1,790
+63
| +4% | +$292K | ﹤0.01% | 2942 |
|
|
2017
Q4 | $6.64M | Buy |
1,727
+565
| +49% | +$2.25M | ﹤0.01% | 3019 |
|
|
2017
Q3 | $5.43M | Buy |
1,162
+45
| +4% | +$200K | ﹤0.01% | 3087 |
|
|
2017
Q2 | $5.04M | Buy |
+1,117
| New | +$6.28M | ﹤0.01% | 3083 |
|
Other funds holding FBRX
FAM
O
AAA
CCC
WP
Vanguard Group's FBRX Position: Q4 2025 in Review
Vanguard Group increased its Forte Biosciences (FBRX) stake by 2.7% in Q4 2025, buying an estimated $272K and bringing the position to 582,263 shares worth $15.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2730.
Vanguard Group first reported a position in FBRX in Q2 2017 and has held it in 35 quarters since. The position peaked at $17.7M in Q2 2021. 59 funds tracked by Wall St. Rank hold FBRX as of Q4 2025.
- Vanguard Group held 582,263 shares of Forte Biosciences worth $15.9M as of Q4 2025.
- Vanguard Group bought 15,522 Forte Biosciences shares in Q4 2025, an estimated $272K.
- Forte Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2730 holding.
- Vanguard Group first reported a position in Forte Biosciences in Q2 2017 and has held it in 35 quarters since.
- Vanguard Group's Forte Biosciences position peaked at $17.7M in Q2 2021.
- 59 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.